HER2零表达与低表达乳腺癌的临床特征和新辅助治疗效果分析

陈美霖 ,  陈麒帆 ,  李牧遥 ,  金锋 ,  金紫凝 ,  郑昂

中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (6) : 487 -495.

PDF (490KB)
中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (6) : 487 -495. DOI: 10.12007/j.issn.0258‐4646.2026.06.002
论著

HER2零表达与低表达乳腺癌的临床特征和新辅助治疗效果分析

作者信息 +

Clinical characteristics and neoadjuvant treatment efficacy of HER2 zero-expression and low-expression breast cancer

Author information +
文章历史 +
PDF (500K)

摘要

目的 探讨人表皮生长因子受体2 (HER2) 零表达 (HER2-0) 与HER2低表达乳腺癌患者的临床特征以及新辅助治疗效果的差异。方法 收集2016年1月至2020年12月中国医科大学附属第一医院乳腺外科收治的303例HER2-0与HER2低表达乳腺癌患者的临床资料,主要研究终点是乳腺病理完全缓解 (bpCR)。采用t检验和χ2检验比较HER2-0与HER2低表达乳腺癌患者各项临床指标的差异。采用logistic单因素和多因素回归分析,并结合基于倾向评分的治疗加权逆概率 (IPTW) 比较HER2-0与HER2低表达乳腺癌患者,以及不同激素受体 (HR) 表达患者间新辅助治疗效果的差异。结果 HER2-0与HER2低表达患者确诊时的年龄、绝经状态、生育史、锁骨淋巴结侵犯、胸肌腋窝淋巴结侵犯、术前临床T分期和N分期、TNM分期和手术方式比较均无统计学差异 (均P > 0.05)。HER2低表达和HER2-0患者新辅助治疗后bpCR比较无统计学差异 (P > 0.05)。在HR阴性患者中,HER2低表达患者新辅助治疗后bpCR显著优于HER2-0患者 (P < 0.05);而在HR阳性患者中,HER2低表达与HER2-0患者的bpCR比较无统计学差异 (P > 0.05)。结论 HER2-0与HER2低表达乳腺癌患者的临床特征未见明显差异。HR阴性患者中HER2低表达患者新辅助治疗效果显著优于HER2-0患者。不同HR表达水平的HER2低表达乳腺癌可能是一种独特的亚型,值得更多关注。

Abstract

Objective To explore the differences in clinical characteristics and neoadjuvant treatment outcomes between patients with human epidermal growth factor receptor 2 (HER2) zero-expression (HER2-0) and HER2-low expression breast cancer. Methods Clinical data from 303 patients with HER2-0 and HER2-low breast cancer treated at the Department of Breast Surgery,the First Hospital of China Medical University,were collected from January 2016 to December 2020. The primary study endpoint was breast pathological complete response (bpCR). The t and χ2 test were used to compare the differences in clinical indicators between HER2-0 and HER2-low breast cancer patients. Univariate and multivariate logistic regression analyses were performed,combined with inverse probability of treatment weighting (IPTW) based on propensity scores,to compare differences in neoadjuvant therapy efficacy between patients with HER2-0 and HER2-low breast cancer and among patients with different hormone receptor (HR) expression statuses. Results No statistically significant differences were observed between HER2-0 and HER2-low patients in terms of age at diagnosis,menopausal status,reproductive history,supraclavicular lymph node involvement,pectoral axillary lymph node involvement,preoperative clinical tumor (T) and node (N) stages;tumor,node,and metastasis (TNM) stage;and surgical approach (all P > 0.05). No statistically significant differences in bpCR after neoadjuvant therapy were observed between HER2-low and HER2-0 patients (P > 0.05). Among HR-negative patients,HER2-low patients showed significantly better bpCR after neoadjuvant therapy compared with HER2-0 patients (P < 0.05). However,among HR-positive patients,no statistically significant differences in bpCR were observed between HER2-low and HER2-0 patients (P > 0.05). Conclusion No significant differences in clinical characteristics were observed between HER2-0 and HER2-low breast cancer patients. The neoadjuvant treatment effect of HER2 low-expression patients is significantly better than that of HER2-0 patients among HR-negative patients. Therefore,HER2-low breast cancer with different HR expression levels may represent a distinct subtype that warrants further study.

关键词

乳腺癌 / HER2低表达 / HER2零表达 / 临床特征 / 新辅助治疗

Key words

breast cancer / HER2-low expression / HER2-zero expression / clinical characteristic / neoadjuvant treatment

引用本文

引用格式 ▾
陈美霖,陈麒帆,李牧遥,金锋,金紫凝,郑昂. HER2零表达与低表达乳腺癌的临床特征和新辅助治疗效果分析[J]. 中国医科大学学报, 2026, 55(6): 487-495 DOI:10.12007/j.issn.0258‐4646.2026.06.002

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

YANG C,BREZDEN-MASLEY C,JOY AA,et al. Targeting HER2-low in metastatic breast cancer:an evolving treatment paradigm [J]. Ther Adv Med Oncol,2023,15:17588359231175440. DOI:10.1177/17588359231175440.

[2]

MA YZ,YANG Y,ZHU MD,et al. Changes in HER2,ER,PR,and ki-67 in HER2-negative breast cancer after neoadjuvant chemotherapy:a case-control study [J]. Curr Oncol,2025,33 (1):6. DOI:10.3390/curroncol33010006.

[3]

MODI SN,JACOT W,YAMASHITA T,et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [J]. N Engl J Med,2022,387 (1):9-20. DOI:10.1056/NEJMoa2203690.

[4]

T-DXd keeps shining in breast cancer [J]. Cancer Discov,2023,13 (2):254. DOI:10.1158/2159-8290.CD-ND2022-0020.

[5]

T-DXd:new standard for HER2-low breast cancer [J]. Cancer Discov,2022,12 (8):1828. DOI:10.1158/2159-8290.CD-NB2022-0043.

[6]

国际医学学会,中国抗癌协会,乳腺癌专业委员会,等. 低表达人表皮生长因子受体2 (HER2) 乳腺癌临床诊断与治疗共识 (2022版) [J]. 中华肿瘤杂志,2022,44 (12):1288-1295. DOI:10.3760/cma.j.cn112152-20220914-00623.

[7]

ALMSTEDT K,HEIMES AS,KAPPENBERG F,et al. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer [J]. Eur J Cancer,2022,173:10-19. DOI:10.1016/j.ejca.2022.06.012.

[8]

LI YQ,ABUDUREHEIYIMU N,MO HN,et al. In real life,low-level HER2 expression may be associated with better outcome in HER2-negative breast cancer:a study of the national cancer center,China [J]. Front Oncol,2021,11:774577. DOI:10.3389/fonc.2021.774577.

[9]

ROSSO C,VOUTSADAKIS IA. Characteristics,clinical differences and outcomes of breast cancer patients with negative or low HER2 expression [J]. Clin Breast Cancer,2022,22 (4):391-397. DOI:10.1016/j.clbc.2022.02.008.

[10]

SHAO YB,YU Y,LUO ZF,et al. Clinical,pathological complete response,and prognosis characteristics of HER2-low breast cancer in the neoadjuvant chemotherapy setting:a retrospective analysis [J]. Ann Surg Oncol,2022,29 (13):8026-8034. DOI:10.1245/s10434-022-12369-4.

[11]

VIALE G,BASIK M,NIIKURA N,et al. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics,treatments received,and outcomes of HER2-low breast cancer [J]. ESMO Open,2023,8 (4):101615. DOI:10.1016/j.esmoop.2023.101615.

[12]

DENKERT C,SEITHER F,SCHNEEWEISS A,et al. Clinical and molecular characteristics of HER2-low-positive breast cancer:pooled analysis of individual patient data from four prospective,neoadjuvant clinical trials [J]. Lancet Oncol,2021,22 (8):1151-1161. DOI:10.1016/S1470-2045(21)00301-6.

[13]

YANG X,LI Y,LU X,et al. Clinicopathological features and prognosis of patients with HER2-low breast cancer [J]. BMC Cancer,2023,23 (1):914. DOI:10.1186/s12885-023-11421-0.

[14]

ZHANG GC,REN CY,LI C,et al. Distinct clinical and somatic mutational features of breast tumors with high-,low-,or non-expressing human epidermal growth factor receptor 2 status [J]. BMC Med,2022,20 (1):142. DOI:10.1186/s12916-022-02346-9.

[15]

SHAO YB,LUO ZF,YU Y,et al. HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor:a real-world study [J]. Front Endocrinol,2022,13:1000704. DOI:10.3389/fendo.2022.1000704.

[16]

中国抗癌协会乳腺癌专业委员会,中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范 (2026年版) [J]. 肿瘤影像学,2026,35 (1):114-212. DOI:10.19732/j.cnki.2096-6210.2026.01.015.

[17]

邵志敏,吴炅,江泽飞,等. 中国乳腺癌新辅助治疗专家共识 (2022年版) [J].中国癌症杂志,2022,32 (1):80-89. DOI:10.19401/j.cnki.1007-3639.2022.01.011.

[18]

KANG S,LEE SH,LEE HJ,et al. Pathological complete response,long-term outcomes,and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy [J]. Eur J Cancer,2022,176:30-40. DOI:10.1016/j.ejca.2022.08.031.

[19]

TARANTINO P,JIN QC,TAYOB N,et al. Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer [J]. JAMA Oncol,2022,8 (8):1177-1183. DOI:10.1001/jamaoncol.2022.2286.

[20]

DE MOURA LEITE L,CESCA MG,TAVARES MC,et al. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer [J]. Breast Cancer Res Treat,2021,190 (1):155-163. DOI:10.1007/s10549-021-06365-7.

[21]

DE NONNEVILLE A,HOUVENAEGHEL G,COHEN M,et al. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers [J]. Eur J Cancer,2022,176:181-188. DOI:10.1016/j.ejca.2022.09.017.

[22]

ZHANG XY,YANG DY,LIN XW,et al. Advances in immunotherapy for HER2 low-expressing triple-negative breast cancer [J]. Cancer Manag Res,2025,17:2985-2995. DOI:10.2147/CMAR.S566797.

[23]

ZHONG HY,ZHOU ZL,WANG H,et al. The biological roles and clinical applications of the PI3K/AKT pathway in targeted therapy resistance in HER2-positive breast cancer:a comprehensive review [J]. Int J Mol Sci,2024,25 (24):13376. DOI:10.3390/ijms252413376.

[24]

KANG YJ,LIU YQ,LIANG Z,et al. The landscape of potential targeted treatments and chemotherapy efficacy biomarkers for TNBC [J]. Breast Cancer (Dove Med Press),2025,17:1341-1367. DOI:10.2147/BCTT.S553421.

[25]

XIANG DL,YUE X. Research progress of molecular typing and targeted therapy for triple-negative breast cancer [J]. Front Oncol,2025,15:1666126. DOI:10.3389/fonc.2025.1666126.

[26]

MARCHIÒ C,ANNARATONE L,MARQUES A,et al. Evolving concepts in HER2 evaluation in breast cancer:heterogeneity,HER2-low carcinomas and beyond [J]. Semin Cancer Biol,2021,72:123-135. DOI:10.1016/j.semcancer.2020.02.016.

[27]

LAMBEIN K,VAN BOCKSTAL M,VANDEMAELE L,et al. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer:clinical and pathobiological relevance [J]. Am J Clin Pathol,2013,140 (4):561-566. DOI:10.1309/AJCP4A7KTAYHZSOE.

[28]

TARANTINO P,GANDINI S,NICOLÒ E,et al. Evolution of low HER2 expression between early and advanced-stage breast cancer [J]. Eur J Cancer,2022,163:35-43. DOI:10.1016/j.ejca.2021.12.022.

基金资助

国家卫生健康委能力建设和继续教育中心2025年慢病管理研究课题(GWJJMB202510022193)

辽宁省科技计划联合计划项目技术攻关项目(2024JH2/102600315)

AI Summary AI Mindmap
PDF (490KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉